Forte Biosciences, Inc.
FBRX
$17.00
$1.338.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 10.70% | -40.19% | -57.19% | 28.15% | -118.81% |
| Total Depreciation and Amortization | 0.00% | 11.76% | 13.33% | 15.38% | 30.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 89.48% | 13.58% | -1.47% | 8.33% | 155.08% |
| Change in Net Operating Assets | -97.90% | 202.46% | 780.75% | -108.24% | 214.77% |
| Cash from Operations | -14.22% | -17.61% | -39.15% | 2.84% | -3.46% |
| Capital Expenditure | -- | 100.00% | -- | 100.00% | -96.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | 201.10% |
| Cash from Investing | -- | 100.00% | -- | -100.00% | 200.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 573.33% | -99.17% | -97.59% | 833,255.56% | -99.98% |
| Repurchase of Common Stock | -350.00% | -20.00% | -66.67% | 80.00% | -650.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 89.78% | -100.78% | -106.60% |
| Cash from Financing | 722.22% | -99.32% | -98.12% | 3,129.67% | -104.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.84% | -29.28% | -121.12% | 155.33% | 301.50% |